ISTA Pharmaceuticals Inc. has announced the preliminary analysis of a late-stage trial in Xibrom QD. Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain following cataract surgery. The result shows to have achieved statistical significance in meeting the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. The company recently completed Phase III clinical program of Xibrom QD. The program enrolled 282 patients who underwent cataract surgery in two U.S. multi-center, parallel-group, vehicle-controlled studies to evaluate Xibrom 0.09% dosed once daily to vehicle (placebo).

The U.S. attorney’s office in Buffalo has issued a subpoena to the Ista Pharmaceuticals Inc. requesting it to produce documents regarding an anti-inflammatory drug. The drug in question is Xibrom, used in treatment of inflammatory infections of the eye after cataract surgery. The company has said in a statement that it will be cooperating with the request, though it did not specify the reason for such a request.